Vismodegib and the Hedgehog Pathway Inhibitors: a Historical Perspective to Current Clinical Application

Tang, J.C.; Hanke, C.W.; Caro, I.

Journal of Drugs in Dermatology Jdd 17(5): 506-508

2018


ISSN/ISBN: 1545-9616
PMID: 29742180
Document Number: 17604
Vismodegib (Erivedge, Genentech-Roche) is the first in class of Hedgehog pathway inhibitors approved for treatment of metastatic basal cell carcinoma (BCC), or locally advanced BCC that has recurred after surgery or is not amenable to surgery or radiation. Its path to discovery has been unique and traces its origin to corn lilies, sheep, Drosophila flies, and the Hedgehog signaling pathway.

Document emailed within 1 workday
Secure & encrypted payments

Vismodegib and the Hedgehog Pathway Inhibitors: a Historical Perspective to Current Clinical Application